Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications

Blood Adv. 2018 Jan 23;2(2):116-119. doi: 10.1182/bloodadvances.2017010512.

Abstract

  1. Patients of minority race with myeloma have had less increase in population-level survival in the early 21st century than white patients.

  2. Data from clinical trials show that mortality is similar for minorities, suggesting the population-level difference is due to utilization.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Clinical Trials as Topic
  • Ethnicity
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunomodulation / drug effects
  • Male
  • Middle Aged
  • Minority Groups
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / epidemiology
  • Multiple Myeloma / ethnology
  • Multiple Myeloma / mortality*
  • Proteasome Inhibitors / therapeutic use

Substances

  • Immunologic Factors
  • Proteasome Inhibitors